FOLH1 and prostate carcinoma: Positron emission tomography (PET) using prostate-specific membrane antigen (PSMA)-targeted radiopharmaceuticals is transforming clinical care for prostate cancer (PCa) patients by providing physicians with more accurate information during staging of primary and recurrent disease (Fendler et al. 2023; Houshmand et al. 2023).